静脉注射恩拉嗪对原发性高血压的影响。

Effects of intravenous endralazine in essential hypertension.

作者信息

Hoffmann J J, Thien T, van T'Laar A

出版信息

Br J Clin Pharmacol. 1983 Jul;16(1):39-44. doi: 10.1111/j.1365-2125.1983.tb02141.x.

DOI:10.1111/j.1365-2125.1983.tb02141.x

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1427955/

Abstract

The effects of endralazine, administered intravenously, on blood pressure, heart rate, forearm blood flow, plasma renin activity, aldosterone, adrenaline and noradrenaline were studied in five patients with essential hypertension. Endralazine reduced peripheral vascular resistance, resulting in decrease in mean arterial pressure from 141 to 116 mm Hg and increase in heart rate from 67 to 92 beats/min. Plasma renin activity, adrenaline and noradrenaline increased significantly after endralazine infusion. All effects observed are consistent with endralazine acting as a peripheral vasodilating drug.

摘要

在5例原发性高血压患者中研究了静脉注射恩屈嗪对血压、心率、前臂血流量、血浆肾素活性、醛固酮、肾上腺素和去甲肾上腺素的影响。恩屈嗪降低外周血管阻力，导致平均动脉压从141毫米汞柱降至116毫米汞柱，心率从67次/分钟增至92次/分钟。静脉输注恩屈嗪后，血浆肾素活性、肾上腺素和去甲肾上腺素显著增加。观察到的所有效应均与恩屈嗪作为一种外周血管扩张药物的作用一致。

相似文献

1

Effects of intravenous endralazine in essential hypertension.

Br J Clin Pharmacol. 1983 Jul;16(1):39-44. doi: 10.1111/j.1365-2125.1983.tb02141.x.

2

Changes in renal function induced by endralazine, a new antihypertensive drug.

Eur J Clin Pharmacol. 1983;24(3):307-14. doi: 10.1007/BF00610046.

3

Intravenous pinacidil in the acute treatment of hypertension.

J Clin Pharmacol. 1987 Jul;27(7):468-74. doi: 10.1002/j.1552-4604.1987.tb03051.x.

4

Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.

Clin Exp Hypertens A. 1982;4(8):1409-18. doi: 10.3109/10641968209060798.

5

The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects.

Br J Clin Pharmacol. 1983 Jul;16(1):27-32. doi: 10.1111/j.1365-2125.1983.tb02139.x.

6

Evaluation of once daily endralazine in hypertension.

Eur J Clin Pharmacol. 1986;30(5):553-7. doi: 10.1007/BF00542414.

7

Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.

Clin Exp Pharmacol Physiol. 1981 Mar-Apr;8(2):133-9. doi: 10.1111/j.1440-1681.1981.tb00144.x.

8

A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile.

Int J Clin Pharmacol Res. 1986;6(4):275-81.

9

[Effect of nifedipine on effective renal plasma flow, plasma renin activity and serum aldosterone, noradrenaline and adrenaline levels in healthy persons and in patients with primary moderate arterial hypertension].

Pol Tyg Lek. 1989;44(30-31):707-9.

10

A dose-finding study of the combination of pindolol, clopamide and endralazine in the treatment of moderate-to-severe hypertension.

S Afr Med J. 1984 Nov 3;66(18):682-4.

引用本文的文献

1

Comparison of once daily endralazine with placebo in the treatment of hypertension uncontrolled by a beta-blocker and diuretic.

Eur J Clin Pharmacol. 1985;29(4):401-3. doi: 10.1007/BF00613452.

本文引用的文献

1

Kinetics of hydralazine and its main metabolites in slow and fast acetylators.

Clin Pharmacol Ther. 1980 Dec;28(6):769-78. doi: 10.1038/clpt.1980.234.

2

[Management of treatment-resistant hypertension: comparison of the antihypertensive effect of endralazine and minoxidil (author's transl)].

Dtsch Med Wochenschr. 1981 Sep 11;106(37):1176-81. doi: 10.1055/s-2008-1070477.

3

The effects of a new anti-hypertensive agent (endralazin) upon the general and coronary haemodynamics of the anaesthetized dog.

Eur J Pharmacol. 1981 Feb 19;69(4):471-6. doi: 10.1016/0014-2999(81)90451-9.

4

Radioenzymatic assay of plasma adrenaline and noradrenaline: evidence for a catechol-O-methyltransferase (COMT) inhibiting factor associated with essential hypertension.

Clin Chim Acta. 1982 Nov 10;125(3):319-27. doi: 10.1016/0009-8981(82)90263-7.

5

Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.

Clin Exp Pharmacol Physiol. 1981 Mar-Apr;8(2):133-9. doi: 10.1111/j.1440-1681.1981.tb00144.x.

6

Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.

Clin Exp Hypertens A. 1982;4(8):1409-18. doi: 10.3109/10641968209060798.

7

Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.

J Cardiovasc Pharmacol. 1982 Jul-Aug;4(4):562-6. doi: 10.1097/00005344-198207000-00006.

8

Vasodilator drugs in the treatment of hypertension.

Arch Intern Med. 1974 Jun;133(6):1017-27.

9

The reliability of the measurement of plasma renin activity by radioimmunoassay.

Clin Chim Acta. 1975 Jun 20;61(3):309-24. doi: 10.1016/0009-8981(75)90421-0.

10

[Hemodynamic study on a new antihypertensive drug (a pyridopyridazine) in the treatment of hypertensive crisis and resistent hypertension. First findings in man (author's transl)].

Z Kardiol. 1977 Apr;66(4):203-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。